海外の治験の状況「前立腺癌」での検索結果
167件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- -C61 Malignant neoplasm of prostate Malignant neoplasm of prostate;Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Korea South, Latvia, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kindgdom, United States
- 2015-04-29
Not Recruiting
- Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Hungary, Korea, Republic of, Netherlands, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Taiwan, Province of China, Tunisia, Turkey, United Kingdom, United States
- 2015-03-11
Not recruiting
- Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer
- Prostate Cancer Non-Metastatic;Castration-Resistant
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2014-07-22
Not recruiting
- A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
- Prostate Neoplasms
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Peru, Poland, Portugal, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
- 2012-10-24
Not recruiting
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
- Metastatic Castration-resistant Prostate Cancer
- Argentina, Australia, Austria, Brazil, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Norway, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2016-11-15
Not recruiting
- Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer
- Prostatic Neoplasms
- Brazil
- 2012-03-30
Not Recruiting
- A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 (Zibotentan) in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-resistant Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Brazil, Canada, Czech Republic, Finland, France, Germany, Hungary, India, Italy, Korea, Republic of, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, South Africa, Spain, Sweden, Switzerland, Taiwan, Province of China, United Kingdom, United States
- 2013-11-13
Not Recruiting
- Evaluation of the effect of Electrical Stimulation on erectile dysfunction after Prostate Cancer surgery
- Man; Erectile dysfunction of organic origin; malignant neoplasm of the prostate C61 N48.4 M01.390;M01.390
- Brazil
- 2017-08-24
Not Recruiting
- A study of patients with prostate cancer who have previously been treated with docetaxel-based chemotherapy, where patients receive either study drug or placebo
- Patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy MedDRA version: 14.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Canada, Chile, France, Germany, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom, United States
- 2009-09-03
- PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TASQUINIMOD IN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Estonia, France, Germany, Greece, India, Israel, Italy, Korea North, Lebano, Lithuania, Mexico, Netherlands, New Zealand, Panama, Poland, Romania, Russian Federation, Slovakia, Spain, Switzerland, Taiwan, Turkey, Ukraine, United Kindgdom, United States
- 2011-08-24